Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Nov 27, 2022 2:59pm
75 Views
Post# 35132219

RE:RE:RE:Hypothetical

RE:RE:RE:HypotheticalI totally agree with you BellEnd if they win this judgement they will not only get the rights to Asia back they will most likely receive compensation related to the missed milestone payments. I would also assume Shiseido will have to turn over to Replicel all Trial results including this latest Trial data.

With that in mind when the hearing is announced Shiseido will be advised by there lawyers to settle with Replicel in order to not loose everything.

If and when this happens it will be a big day for the Replicel share price.  For all those dreamers lets refrain from talking about $10.00 - $20.00 share prices.  That first day we may see $1.00+.  After that depending on the size of the settlement it will build from there.  Also around the same time we should hear that the Dermaprecise has been submitted for FDA Approval .  This should take us closer to $2.00+  After that we should see a slow build. 
Again speculating if we see both of these events take place Replicel will be in the crosshairs of big pharma and sky is the limit.
<< Previous
Bullboard Posts
Next >>